Literature DB >> 26107214

Cancer/Testis OIP5 and TAF7L Genes are Up-Regulated in Breast Cancer.

Maryam Beigom Mobasheri1, Reza Shirkoohi, Mohammad Hossein Modarressi.   

Abstract

Breast cancer still remains as the most frequent cancer with second mortality rate in women worldwide. There are no validated biomarkers for detection of the disease in early stages with effective power in diagnosis and therapeutic approaches. Cancer/testis antigens are recently promising tumor antigens and suitable candidates for targeted therapies and generating cancer vaccines. We conducted the present study to analyze transcript changes of two cancer/testis antigens, OIP5 and TAF7L, in breast tumors and cell lines in comparison with normal breast tissues by quantitative real time RT-PCR for the first time. Significant over-expression of OIP5 was observed in breast tumors and three out of six cell lines including MDA-MB-468, T47D and SKBR3. Not significant expression of TAF7L was evident in breast tumors but significant increase was noted in three out of six cell lines including MDA-MB-231, BT474 and T47D. OIP5 has ssignificant role in chromatin organization and cell cycle control during cell cycle exit and normal chromosome segregation during mitosis and TAF7L is a component of the transcription factor ??D, which is involved in transcription initiation of most protein coding genes. TAF7Lis located at X chromosome and belongs to the CT-X gene family of cancer/testis antigens which contains about 50% of CT antigens, including those which have been used in cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26107214     DOI: 10.7314/apjcp.2015.16.11.4623

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

1.  Cancer-testis specific gene OIP5: a downstream gene of E2F1 that promotes tumorigenesis and metastasis in glioblastoma by stabilizing E2F1 signaling.

Authors:  Jiang He; Yuzu Zhao; Erhu Zhao; Xianxing Wang; Zhen Dong; Yibiao Chen; Liqun Yang; Hongjuan Cui
Journal:  Neuro Oncol       Date:  2018-08-02       Impact factor: 12.300

2.  OIP5 Expression Sensitize Glioblastoma Cells to Lomustine Treatment.

Authors:  Dorival Mendes Rodrigues-Junior; Thaís Priscila Biassi; Viviane Carlin; Marcus Vinicius Buri; Ana Claudia Torrecilhas; Karina Ramalho Bortoluci; André Luiz Vettore
Journal:  J Mol Neurosci       Date:  2018-10-03       Impact factor: 3.444

3.  Synaptonemal Complex Protein 3 Transcript Analysis in Breast Cancer.

Authors:  Maryam Beigom Mobasheri; Reza Shirkoohi; Mohammad Hossein Modarressi
Journal:  Iran J Public Health       Date:  2016-12       Impact factor: 1.429

Review 4.  Cancer/Testis genes in relation to sperm biology and function.

Authors:  Kehinde Adebayo Babatunde; Ali Najafi; Pouya Salehipour; Mohammad Hossein Modarressi; Maryam Beigom Mobasheri
Journal:  Iran J Basic Med Sci       Date:  2017-09       Impact factor: 2.699

5.  Overexpression of Opa interacting protein 5 increases the progression of liver cancer via BMPR2/JUN/CHEK1/RAC1 dysregulation.

Authors:  Yuwen Li; Fei Xiao; Wenting Li; Pingping Hu; Ruirui Xu; Jun Li; Guimei Li; Chuanlong Zhu
Journal:  Oncol Rep       Date:  2019-02-11       Impact factor: 3.906

6.  Assessment of biochemical recurrence of prostate cancer (Review).

Authors:  Xiaozeng Lin; Anil Kapoor; Yan Gu; Mathilda Jing Chow; Hui Xu; Pierre Major; Damu Tang
Journal:  Int J Oncol       Date:  2019-10-04       Impact factor: 5.650

7.  OIP5 Is a Novel Prognostic Biomarker in Clear Cell Renal Cell Cancer Correlating With Immune Infiltrates.

Authors:  Mancheng Gong; Yongxiang Li; Erlin Song; Miaoyuan Li; Shaopeng Qiu; Wenjing Dong; Runqiang Yuan
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

8.  LncRNA OIP5-AS1 is overexpressed in undifferentiated oral tumors and integrated analysis identifies as a downstream effector of stemness-associated transcription factors.

Authors:  Ganesan Arunkumar; Shankar Anand; Partha Raksha; Shankar Dhamodharan; Harikrishnan Prasanna Srinivasa Rao; Shanmugam Subbiah; Avaniyapuram Kannan Murugan; Arasambattu Kannan Munirajan
Journal:  Sci Rep       Date:  2018-05-04       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.